Skip to content
Home
Product
Technology
Education
Clinical Trials
Company
News
Contact Us
Home
Product
Technology
Education
Clinical Trials
Company
News
Contact Us
News
THE AMA CPT® Extends Category III Code Applicable to Orlucent® Inc.’s Molecular Test for Biological Activity in Suspicious Nevi
March 4, 2026
READ MORE
Online Journal, The Pathologist, Features Interview with Orlucent® Co-Founder and Chief Scientific Officer
February 11, 2026
READ MORE
Orlucent® Receives the 2026 Handheld Fluorescent Molecular Imaging System of the Year Award
January 28, 2026
READ MORE
Overview of Molecular Imaging Methods in Early Skin Cancer Detection Highlights Benefits of the Orlucent® Skin Fluorescent Imaging System
January 22, 2026
READ MORE
Clinical Trial Demonstrates Accurate Non-Invasive Detection of In Vivo Biologic Activity in Melanomas by the Orlucent® Skin Fluorescent Imaging System
January 20, 2026
READ MORE
Stromal Tumor Environment May Be Early Indicator of Melanoma Progression
May 15, 2025
READ MORE
Orlucent® Receives California Food and Drug Branch Manufacturing License
March 9, 2025
READ MORE
Orlucent® Supports Research on Updated Criteria for Histopathologic Scoring and Grading of Melanocytic Dysplasia
November 4, 2024
READ MORE
Orlucent® Proof of Concept Activity Image Featured in Cover Story of Pigment Cell & Melanoma Research
May 8, 2024
READ MORE
Orlucent® Featured in Clinical Lab Products Magazine
February 14, 2024
READ MORE
SHOW MORE
